Veirulence Ltd
Veirulence Ltd. is a UK-based biopharmaceutical startup pioneering a first-in-class, non-antibiotic therapeutic approach to combat bacterial infections and the growing global challenge of antimicrobial resistance (AMR). The company is developing a first-in-class small molecule that targets a core genome regulator of c-di-GMP to treat acute Gram-negative bloodstream infections.